|Title:||Psychoactive substance disorders|
|Abstract:||2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders relating to the use of psychoactive substances. The compound has the following structure: ##STR1##|
|Inventor(s):||Beasley, Jr.; Charles M. (Indianapolis, IN), Chakrabarti; Jiban Kumar (Camberley, GB2), Hotten; Terrence Michael (Farnborough, GB2), Tupper; David Edward (Reading, GB2)|
|Assignee:||Eli Lilly and Company (Indianapolis, IN) Eli Lilly and Company Limited (Basingstoke, GB2)|
Patent Claim Types:|
see list of patent claims
Field: Basic materials chemistry
Back Citations: 7th percentile
Forward Citations: 2nd percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.